Neuroproteases in peptide neurotransmission and neurodegenerative diseases: Applications to drug discovery research

BioDrugs

Volumn 20, Issue 2, 2006, Pages 105-119

  Hook, Vivian Y H ^a,b,c  

^a University of California San Diego   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BRAIN PEPTIDE; CA 074; CATHEPSIN B; CATHEPSIN B INHIBTOR; CATHEPSIN L; CHOLINESTERASE INHIBITOR; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; DYNORPHIN; ENDORPHIN; ENKEPHALIN; FURIN; GALANIN; HUNTINGTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARKIN; PROTEINASE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SOMATOSTATIN; SUBTILISIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANALGESIA; ANALYTIC METHOD; BEHAVIOR; BIOSYNTHESIS; BLOOD PRESSURE REGULATION; CARBOXY TERMINAL SEQUENCE; CHELATION; COGNITION; COGNITIVE DEFECT; CORTICOSTEROID METABOLISM; DEGENERATIVE DISEASE; DRUG TARGETING; ENDOCRINE SYSTEM; FEEDING BEHAVIOR; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; IMMUNOELECTRON MICROSCOPY; KNOCKOUT MOUSE; LEWY BODY; MOLECULAR BIOLOGY; MOTOR DYSFUNCTION; NERVOUS SYSTEM; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PURIFICATION; REVIEW; SUBSTANTIA NIGRA;

EID: 33646261849     PISSN: 11738804     EISSN: 11738804     Source Type: Journal    
DOI: 10.2165/00063030-200620020-00005     Document Type: Review

References (127)

1. Hook VY, Azaryan AV, Hwang SR, et al. Proteases and the emerging role of protease inhibitors in prohormone processing. FASEB J 1994; 8: 1269-78
2. Zhou A, Webb G, Zhu X, et al. Proteolytic processing in the secretory pathway. J Biol Chem 1999; 274: 20745-8
3. Seidah NG, Prat A. Precursor convertases in the secretory pathway, cytosol and extracellular milieu. Essays Biochem 2002; 38: 79-94
4. Iverson LL, Mortishire-Smith RJ, Pollack SJ, et al. The toxicity in vitro of β-amyloid protein. Biochem J 1995; 311: 1-16
5. Sisodia SS. Alzheimer's disease: perspectives for the new millennium. J Clin Invest 1999; 104: 1169-70
6. Selkoe DJ. Alzheimer's disease: genes, proteins, therapy. Physiol Rev 2001; 81: 741-61
7. Hook VYH, Reisine TD. Cysteine proteases are the major β-secretase in the regulated secretory pathway that provides most of the β-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway. J Neurosci Res 2003; 74: 393-405
8. Mende-Mueller LM, Toneff T, Hwang S-R, et al. Tissue-specific proteolysis of huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum. J Neurosci 2001; 21: 1830-7
9. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990-3
10. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998; 57: 369-84
11. Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 2004; 5: 958-63
12. Burke RE. Recent advances in research on Parkinson disease: synuclein and parkin. Neurologist 2004; 10: 75-81
13. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003; 302: 819-22
14. Giasson BI, Lee VM. Parkin and the molecular pathways of Parkinson's disease. Neuron 2001; 31: 885-8
15. Richardson DE. Central stimulation-induced analgesia in humans: modulation by endogenous opioid peptides. Crit Rev Neurobiol 1990; 6: 33-7
16. Law PY, Loh HH. Regulation of opioid receptor activities. J Pharmacol Exp Ther 1999; 289: 607-24
17. Kanjhan R. Opioids and pain. Clin Exp Pharmacol Physiol 1995; 22: 397-403
18. Bodnar RJ, Klein GE. Endogenous opiates and behavior: 2004. Peptides 2005 Dec; 26 (12): 2629-711
19. Zimanyi IA, Fathi Z, Poindexter GS. Central control of feeding behavior by neuropeptide Y. Curr Pharm Des 1998; 4: 349-66
20. Wieland HA, Hamilton BS, Krist B, et al. The role of NPY in metabolic homeostasis: implications for obesity therapy. Expert Opin Investig Drugs 2000; 9: 1327-46
21. Beck B. Neuropeptides and obesity. Nutrition 2000; 16: 916-23
22. Walker P, Grouzmann E, Burnier M, et al. The role of neuropeptide Y in cardiovascular regulation. Trends Pharmacol Sci 1991; 12: 111-5
23. Munglani R, Hudspith MJ, Hunt SP. The therapeutic potential of neuropeptide Y: analgesic, anxiolytic and antihypertensive. Drugs 1996; 52: 371-89
24. Steiner RA, Hohmann JG, Holmes A, et al. Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer's disease. Proc Natl Acad Sci U S A 2001; 98: 4184-9
25. Schott PA, Hokfelt T, Ogren SO. Galanin and spatial learning in the rat: evidence for a differential role for galanin in subregions of the hippocampal formation. Neuropharmacology 2000; 39: 1386-403
26. Holsboer F. Corticotropin-releasing hormone modulators and depression. Curr Opin Investig Drugs 2003; 4: 46-50
27. Holmes A, Heilig M, Rupniak NM, et al. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 2003; 24: 580-8
28. Coulter CL, Ross JT, Owens JA, et al. Role of pituitary POMC-peptides and insulin-like growth factor II in the developmental biology of the adrenal gland. Arch Physiol Biochem 2002; 110: 99-105
29. Lin L, Achermann JC. The adrenal. Horm Res 2004; 62 Suppl. 3: 22-9
30. Jacobson L. Hypothalamic-pituitary-adrenocortical axis regulation. Endocrinol Metab Clin North Am 2005; 34: 271-92
31. Schiller MR, Mende-Mueller L, Moran K, et al. "Prohormone thiol protease" (PTP) processing of recombinant proenkephalin. Biochemistry 1995, 95
32. Yasothornsrikul S, Aaron W, Toneff T, et al. Evidence for the proenkephalin processing enzyme prohormone thiol protease (PTP) as a multicatalytic cysteine protease complex: activation by glutathione localized to secretory vesicles. Biochemistry 1999; 38: 7421-30
33. Yasothornsrikul S, Greenbaum D, Medzihradszky KF, et al. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc Natl Acad Sci U S A 2003; 100: 9590-5
34. Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 2000; 1477: 98-111
35. Ishidoh K, Kominami E. Processing and activation of lysosomal proteinases. Biol Chem 2002; 383: 1827-31
36. Steiner DF. The proprotein convertases. Curr Opin Chem Biol 1998; 2: 31-9
37. Furuta M, Yano H, Zhou A, et al. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci U S A 1997; 94: 6646-51
38. Furuta M, Carroll R, Martin S, et al. Incomplete processing of proinsulin to insulin accompanied by elevation of Des-31,32 proinsulin intermediates in islets of mice lacking active PC2. J Biol Chem 1998; 273: 3431-7
39. Berman Y, Mzhavia N, Polonskaia A, et al. Defective prodynorphin processing in mice lacking prohormone convertase PC2. J Neurochem 2000; 75: 1763-70
40. Allen RG, Peng B, Pellegrino MJ, et al. Altered processing of pro-orphanin FQ/nociceptin and pro-opiomelanocortin-derived peptides in the brains of mice expressing defective prohormone convertase 2. J Neurosci 2001; 21: 5864-70
41. Villeneuve P, Feliciangeli S, Croissandeau G, et al. Altered processing of the neurotensin/neuromedin N precursor in PC2 knock down mice: a biochemical and immunohistochemical study. J Neurochem 2002; 82: 783-93
42. Miller R, Toneff T, Vishnuvardhan D, et al. Selective roles for the PC2 processing enzyme in the regulation of peptide neurotransmitter levels in brain and peripheral neuroendocrine tissues of PC2 deficient mice. Neuropeptides 2003; 37: 140-8
43. Miller R, Aaron W, Toneff T, et al. Obliteration of α-melanocyte-stimulating hormone derived from POMC in pituitary and brains of PC2-deficient mice. J Neurochem 2003; 86: 556-63
44. Zhu X, Zhou A, Dey A, et al. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc Natl Acad Sci U S A 2002; 99: 10293-8
45. Zhu X, Orci L, Carroll R, et al. Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc Natl Acad Sci U S A 2002; 99: 10299-304
46. Ugleholdt R, Zhu X, Deacon CF, et al. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. Endocrinology 2004; 145: 1349-55
47. Cain BM, Connolly K, Blum AC, et al. Genetic inactivation of prohormone convertase (PC1) causes a reduction in cholecystokinin (CCK) levels in the hippocampus, amygdala, pons and medulla in mouse brain that correlates with the degree of colocalization of PC1 and CCK mRNA in these structures in rat brain. J Neurochem 2004; 89: 307-13
48. Pan H, Nanno D, Che FY, et al. Neuropeptide processing profile in mice lacking prohormone convertase-1. Biochemistry 2005; 44: 4939-48
49. Gettins PG. Serpin structure, mechanism, and function. Chem Rev 2002; 102: 4751-804
50. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins: evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001; 276: 33293-6
51. Lomas DA, Carrell RW. Serpinopathies and the conformational dementias. Nat Rev Genet 2002; 3: 759-68
52. Ray CA, Black RA, Kronheim SR, et al. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 β-converting enzyme. Cell 1992; 69: 597-604
53. Takahashi A, Musy PY, Martins LM, et al. CrmA/SPI-2 inhibition of an endogenous ICE-related protease responsible for lamin A cleavage and apoptotic nuclear fragmentation. J Biol Chem 1996; 271: 32487-90
54. Schick C, Pemberton PA, Shi GP, et al. Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis. Biochemistry 1998; 37: 5258-66
55. Hwang S-R, Steineckert B, Toneff T, et al. The novel serpin endopin 2 demonstrates cross-class inhibition of papain and elastase: localization of endopin 2 to regulated secretory vesicles of neuroendocrine chromaffin cells. Biochemistry 2002; 41: 10397-405
56. Hwang S-R, Stoka V, Turk V, et al. The novel bovine serpin endopin 2C demonstrates selective inhibition of the cysteine protease cathepsin L compared to the serine protease elastase, in cross-class inhibition. Biochemistry 2005; 44: 7757-67
57. Hwang S-R, Garza CZ, Wegrzyn JL, et al. Demonstration of GTG as an alternative initiation codon for the serpin endopin 2B-2. Biochem Biophys Res Commun 2005; 327: 837-44
58. Hook VY, Hwang SR. Novel secretory vesicle serpins, endopin 1 and endopin 2: endogenous protease inhibitors with distinct target protease specificities. Biol Chem 2002 Jul-Aug; 383 (7-8): 1067-74
59. Hwang S-R, Steineckert B, Yasothornsrikul S, et al. Molecular cloning of endopin 1, a novel serpin localized to neurosecretory vesicles of chromaffin cells: inhibition of basic residue-cleaving proteases by endopin 1. J Biol Chem 1999; 274: 34164-73
60. Lindberg I, van den Hurk WH, Bui C, et al. Enzymatic characterization of immunopurified prohormone convertase 2: potent inhibition by a 7B2 peptide fragment. Biochemistry 1995; 34: 5486-93
61. Fortenberry Y, Liu J, Lindberg I. The role of the 7B2 CT peptide in the inhibition of prohormone convertase 2 in endocrine cell lines. J Neurochem 1999; 73: 994-1003
62. Cameron A, Fortenberry Y, Lindberg I. The SAAS granin exhibits structural and functional homology to 7B2 and contains a highly potent hexapeptide inhibitor of PC1. FEBS Lett 2000; 473: 135-8
63. Basak A, Koch P, Dupelle M, et al. Inhibitory specificity and potency of proSAAS-derived peptides toward proprotein convertase 1. J Biol Chem 2001; 276: 32720-8
64. Hosaka M, Nagahama M, Kim WS, et al. Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway. J Biol Chem 1991; 266: 12127-30
65. Gensberg K, Jan S, Matthews GM. Subtilisin-related serine proteases in the mammalian constitutive secretory pathway. Semin Cell Dev Biol 1998; 9: 11-7
66. Hook VYH, Toneff T, Aaron W, et al. β-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for β-secretase activity in chromaffin vesicles. J Neurochem 2002; 81: 237-56
67. Hook V, Toneff T, Bogyo M, et al. Inhibition of cathepsin B reduces β-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate β-secretase of Alzheimer's disease. Biol Chem 2005; 386: 931-40
68. Matsumoto K, Mizoue K, Kitamura K, et al. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives. Biopolymers 1999; 51: 99-107
69. Yamamoto A, Hara T, Tomoo K, et al. Binding mode of CA074, a specific irreversible inhibitor, to bovine cathepsin B as determined by X-ray crystal analysis of the complex. J Biochem 1997; 121: 974-7
70. Buttle DJ, Murata M, Knight CG, et al. CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch Biochem Biophys 1992; 299: 377-80
71. Hussain I, Powell D, Howlett DR, et al. Identification of a novel aspartic protease (Asp 2) as β-Secretase. Mol Cell Neurosci 1999; 14: 419-27
72. Sinha S, Anderson JP, Barbour R, et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 1999; 402: 537-40
73. Vassar R, Bennet BD, Babu-Khan S, et al. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735-41
74. Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature 1999; 402: 533-7
75. Lin X, Koelsch G, Wu S, et al. Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein. Proc Natl Acad Sci U S A 2000; 97: 1456-60
76. Deussing J, Roth W, Saftig P, et al. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci U S A 1998; 95: 4516-21
77. Canbay A, Guicciardi ME, Higuchi H, et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest 2003; 112: 152-9
78. Guicciardi ME, Miyoshi H, Bronk SF, et al. Cathepsin B knockout mice are resistant to tumor necrosis factor-α-mediated hepatocyte apoptosis and liver injury. Am J Pathol 2001; 159: 2045-54
79. Halangk W, Lerch MM, Brandt-Nedelev B, et al. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest 2000; 106: 773-81
80. Mukerjee A, Hersh LB. Regulation of amyloid β-peptide levels by enzymatic degradation. J Alzheimers Dis 2002; 4: 341-8
81. Song E-S, Juliano MA, Juliano L, et al. Substrate activation of insulin-degrading enzyme (insulysin): a potential target for drug development. J Biol Chem 2003; 278: 49789-94
82. Muñoz-Ruiz P, Rubio L, García-Palomero E, et al. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J Med Chem 2005; 48: 7223-33
83. Hoozemans JJM, O'Banion MK. The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord 2005; 4: 307-15
84. Stuve O, Youssef S, Steinman L, et al. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 2003; 16: 393-401
85. Cuajungco MP, Frederickson CJ, Bush AI. Amyloid-β metal interaction and metal chelation. Subcell Biochem 2005; 38: 235-54
86. Smith JD, Levin-Allerhand JA. Potential use of estrogen-like drugs for the prevention of Alzheimer's disease. J Mol Neurosci 2003; 20: 277-82
87. Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005; 2: 155-65
88. MacDonald ME, Ambrose CM, Duyao MP, et al. A novel gene containing a trinucleotide repeat that is expanded on Huntington's disease chromosomes. Cell 1993; 72: 971-83
89. Rubinsztein DC, Leggo J, Chiano M, et al. Homozygotes and heterozygotes for ciliary neurotrophic factor null alleles do not show earlier onset of Huntington's disease. Neurology 1997; 49: 890-2
90. Bates GP, Mangiarini L, Mahal A, et al. Transgenic models of Huntington's disease. Hum Mol Genet 1997; 6: 1633-7
91. Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic of the HD mutation. Cell 1997; 90: 537-48
92. Carter RJ, Lione LA, Humby T, et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 1999; 19: 3248-57
93. Hodgson JG, Agopyan N, Gutekunst CA, et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999; 23: 181-92
94. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211
95. Del Tredici K, Rüb U, de Vos RAI, et al. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002; 61: 413-26
96. Riess O, Jakes R, Kruger R. Genetic dissection of familial Parkinson's disease. Mol Med Today 1998; 4310: 438-44
97. Spillantini MG, Crowther RA, Jakes R, et al. α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998; 95: 6469-73
98. Iseki E, Marui W, Kosaka K, et al. Degenerative terminals of the perforant pathway are human α-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease. Neurosci Lett 1998; 258: 81-4
99. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-7
100. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106-8
101. Ueda K, Fukushima HJ, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 11282-6
102. Iwai A, Yoshimoto M, Masliah E, et al. Non-Aβ component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 1995; 34: 10139-45
103. Yoshimoto M, Iwai A, Kang D, et al. NACP, the precursor protein of the non-amyloid β/A4 protein (Aβ) component of Alzheimer disease amyloid, binds Aβ and stimulates Aβ aggregation. Proc Natl Acad Sci U S A 1995; 92: 9141-5
104. Masliah E, Iwai A, Mallory M, et al. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am J Pathol 1996; 148: 201-10
105. Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 1998; 21: 249-54
106. Lavedan C, Leroy E, Dehejia A, et al. Identification, localization, and characterization of the human γ-synuclein gene. Hum Genet 1998; 103: 106-12
107. Petrucelli L, O'Farrell C, Lockhart PJ, et al. Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002; 36: 1007-19
108. Stefanis L, Larsen KE, Rideout HJ, et al. Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001; 21: 9549-60
109. Yamada M, Iwatsubo T, Mizuno Y, et al. Overexpression of α-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α-synuclein, and activation of caspase-9: resemblance to pathogenic changes in Parkinson's disease. J Neurochem 2004; 91: 451-61
110. Liu CW, Giasson BI, Lewis KA, et al. A precipitating role for truncated α-synuclein and the proteasome in α-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem 2005; 280: 22670-8
111. Mishizen-Eberz AJ, Norris EH, Giasson BI, et al. Cleavage of α-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of α-synuclein. Biochemistry 2005; 44: 7818-29
112. Sung JY, Park SM, Lee CH, et al. Proteolytic cleavage of extracellular secreted α-synuclein via matrix metalloproteinases. J Biol Chem 2005; 280: 25216-24
113. Iwata A, Maruyama M, Akagi T, et al. Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum Mol Genet 2003; 12: 2625-35
114. Mishizen-Eberz AJ, Guttmann RP, Giasson BI, et al. Distinct cleavage patterns of normal and pathologic forms of α-synuclein by calpain I in vitro. J Neurochem 2003; 86: 836-47
115. Kim SJ, Sung JY, Um JW, et al. Parkin cleaves intracellular α-synuclein inclusions via the activation of calpain. J Biol Chem 2003; 278: 41890-9
116. Iwai A, Masliah E, Yamamoto M, et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995; 14: 467-75
117. Hsu L, Mallory M, Xia Y, et al. Expression pattern of synucleins (non-Aβ component of Alzheimer's disease amyloid precursor protein/ α-synuclein) during murine brain development. J Neurochem 1998; 71: 338-44
118. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-8
119. Abbas N, Lucking CB, Ricard S, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum Mol Genet 1999; 8: 567-74
120. Jiang H, Ren Y, Zhao J, et al. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 2004; 13: 1745-54
121. Higashi Y, Asanuma M, Miyazaki I, et al. Parkin attenuates manganese-induced dopaminergic cell death. J Neurochem 2004; 89: 1490-7
122. Anderson PL, Fletcher CV. Updated clinical pharmacologic considerations for HIV-1 protease inhibitors. Curr HIV/AIDS Rep 2004; 1: 33-9
123. Musial BL, Chojnacki JK, Coleman CI. Atazanavir: a new protease inhibitor to treat HIV infection. Am J Health Syst Pharm 2004; 61: 1365-74
124. Randolph JT, Degoey DA. Peptidomimetic inhibitors of HIV protease. Curr Top Med Chem 2004; 4: 1079-95
125. Hughes DB, Britton ML. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Pharmacotherapy 2005; 25: 1602-20
126. Sica DA. Pharmacotherapy review: angiotensin-converting enzyme inhibitors. J Clin Hypertens 2005; 7: 485-8
127. Mielniczuk L, Stevenson LW. Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients. Curr Opin Cardiol 2005; 20: 250-5